Corona G, Ratrelli G, Maggi M. The pharmacotherapy of male hypogonadism besides androgens. Expert Opin Pharmacother 2014:1-19. http://informahealthcare.com/doi/abs/10.1517/14656566.2015.993607
Introduction: Adulthood male hypogonadism (HG) is the most common form of HG. Although testosterone (T) replacement therapy (TRT) is the most common way of treating HG, other options are available depending on patient's needs and expectations.
Areas covered: We analyze alternative options to TRT as a medical intervention in treating HG. Gonadotropin (Gn) therapy is the treatment of choice in men with secondary HG (sHG), who require fertility. Gonadotropin-releasing hormone therapy represents an alternative to Gn for inducing spermatogenesis in patients with sHG, however, its use is limited by the poor patient compliance and high cost.
In obese HG men, lifestyle modifications and, in particular, weight loss should be the first step.
Recent data suggest that antiestrogens represent a successful treatment for sHG.
Other potential therapeutic options include the stimulation of hypothalamic activity (i.e., kisspeptin and neurokinin-B agonists).
Conversely, the possibility of increasing Leydig cell steroid production, independently from Gn stimulation, seems unreliable.
Expert opinion: Understanding the nature of male HG and patient's needs are mandatory before choosing among treatment options. For primary HG only TRT is advisable, whereas for the secondary form several alternative possibilities can be offered.
Introduction: Adulthood male hypogonadism (HG) is the most common form of HG. Although testosterone (T) replacement therapy (TRT) is the most common way of treating HG, other options are available depending on patient's needs and expectations.
Areas covered: We analyze alternative options to TRT as a medical intervention in treating HG. Gonadotropin (Gn) therapy is the treatment of choice in men with secondary HG (sHG), who require fertility. Gonadotropin-releasing hormone therapy represents an alternative to Gn for inducing spermatogenesis in patients with sHG, however, its use is limited by the poor patient compliance and high cost.
In obese HG men, lifestyle modifications and, in particular, weight loss should be the first step.
Recent data suggest that antiestrogens represent a successful treatment for sHG.
Other potential therapeutic options include the stimulation of hypothalamic activity (i.e., kisspeptin and neurokinin-B agonists).
Conversely, the possibility of increasing Leydig cell steroid production, independently from Gn stimulation, seems unreliable.
Expert opinion: Understanding the nature of male HG and patient's needs are mandatory before choosing among treatment options. For primary HG only TRT is advisable, whereas for the secondary form several alternative possibilities can be offered.
